NorthWest Biotherapeutics Inc (NWBO)

[beachlifeisfun]

I think that, when this trial went to a Phase-III, and considering the developing GBM oncology research, at crossover, they had no choice but to unblind each crossover patient so that each patient had his/her opportunity to receive his/her choice of care. Think about it, if you had GBM-IV and were in this trial...on crossover, if you knew what group you were in, how would your choices change? If placebo, then go to treatment...if treatment, then go to checkpoint inhibitors. If you do not inform them, then it becomes a liability at that point.

Yep, I've convinced myself...they had to inform the patient whether or not they were in the treatment or placebo group upon crossover...and I think this is part of what Linda Liau meant with her comments